2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
You are currently not logged in to PHD
To view this content, please login to your account, or within the login, click 'Create an Account' for guest access. To access AHA's full array of membership benefits, join or renew today!
Please note: AHA does not associate with, nor endorse YouTube recommendations.
Steve Ommen, MD, FACC from the Mayo Clinic and Carolyn Ho, MD, FAHA from Brigham and Women's Hospital discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. They highlight the introduction of Mavacamten, the first cardiac myosin inhibitor, as a significant change following its FDA approval for symptomatic obstructive HCM.
Recommended Videos
How Self BP Monitoring Informs Clinical Practice: Take Home Message
Best Ways to Implement Self BP Monitoring for your Practice
Resources for Taking a Good Measurement: How Self BP Monitoring Informs Cl...
Advantages of Self Blood Pressure Monitoring in Predicting CV Events
Challenges of Home Blood Pressure Monitoring
Loading...
Save Video
Please note: AHA does not associate with, nor endorse YouTube recommendations.
Video is not available. Please check the URL.